We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 20, 2011
Last Update Posted: September 20, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Medi-Tate Ltd.
The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia (BPH).The TIND is inserted in the bladder neck and prostatic urethra under local anesthesia for few days and taken out some 5 days later in the doctors office.

Condition Intervention Phase
Bladder Neck Obstruction Benign Prostate Hyperplasia Device: Insertion of Temporary Implantable Nitinol Device (TIND) Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: One-arm Feasibility and Prospective Pivotal Study to Assess the Safety and Efficacy of MediTate Temporary Implantable Nitinol Device (TIND) in Subjects Presenting Bladder Outlet Obstruction Secondary to BPH

Resource links provided by NLM:

Further study details as provided by Medi-Tate Ltd.:

Primary Outcome Measures:
  • Device related and unanticipated SAE [ Time Frame: At 3 months ]
    Device related and unanticipated SAEs will be followed. No such SAEs are expected.

Secondary Outcome Measures:
  • Reduce at least 3 point in the International Prostate Symptom Score (IPSS) in at least 75% of subjects [ Time Frame: At 3 months ]
    Questionnaire of IPSS will be done in each visit.

  • Increase of maximal urinary peak flow by at least 3 ml/s in at least 75% of subjects [ Time Frame: At 3 months ]
    Maximal uroflow will be measured in each visit

Enrollment: 6
Study Start Date: September 2011
Study Completion Date: September 2016
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: device
Insertion of Temporary Implantable Nitinol Device (TIND)
Device: Insertion of Temporary Implantable Nitinol Device (TIND)
Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Main IC:

  • Subject signed informed consent prior to the performance of any study procedures.
  • Male with BPH, who are at least 50 years of age and that were diagnosed with BOO.
  • IPSS symptom severity score ≥ 10.
  • Peak urinary flow of < 12 ml/sec
  • No pathology found with kidney US
  • Prostatic urethra length < 30 mm
  • Prostate volume < 35 cc
  • Normal Urinalysis and urine culture.

Exclusion Criteria:

Main EC:

  • Any prior prostate treatment
  • Suspected or proved carcinoma of prostate
  • Urethral stricture
  • Urinary bladder stones
  • Serum prostate specific antigen level > 4 ng/ml (unless proved to be carcinoma free by biopsy).
  • Active urinary tract infection as determined by positive culture, bacterial prostatitis within the past year documented by positive culture.
  • Median prostatic lobe enlargement or a prominent obstructing "ball valve" prostatic lobe.
  • Subject has an interest in future fertility and is not willing to undergo fertility treatments whatsoever.
  • Any serious medical condition likely to impede successful completion of the study

Intraoperative EC:

  • Irregular findings by the implanting physician during the implantation procedure by the cystoscopy that to the best of the implanting physician are exerting non compliance with the exclusion or inclusion criteria and that were not noticed previously during screening
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01436877

Meir Medical center
Kfar Saba, Israel
Sponsors and Collaborators
Medi-Tate Ltd.
Principal Investigator: Roy Farfara, MD Bnai Zion Medical Center, Haifa, Israel
  More Information

Responsible Party: Medi-Tate Ltd.
ClinicalTrials.gov Identifier: NCT01436877     History of Changes
Other Study ID Numbers: MT-01
First Submitted: September 14, 2011
First Posted: September 20, 2011
Last Update Posted: September 20, 2016
Last Verified: September 2015

Keywords provided by Medi-Tate Ltd.:
bladder neck obstruction
Bladder neck obstruction secondary to BPH

Additional relevant MeSH terms:
Prostatic Hyperplasia
Urinary Bladder Neck Obstruction
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Urethral Obstruction
Urethral Diseases
Urologic Diseases
Urinary Bladder Diseases